查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1576840

青光眼市場：按類型、診斷方法、治療、最終用戶、年齡層分類 - 全球預測 2025-2030

Glaucoma Market by Type (Angle-Closure Glaucoma, Normal-Tension Glaucoma, Primary Open-Angle Glaucoma), Diagnosis Method (Gonioscopy, Tonometry, Visual Field Test), Treatment, End-User, Age Group - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年青光眼市場價值為72.3億美元，預計到2024年將達到76億美元，複合年成長率為5.56%，預計到2030年將達到105.6億美元。

KEYWORD 是全球不可逆轉失明的主要原因，由於人口老化加劇和盛行率不斷上升，需要進行廣泛的市場研究。該市場包括用於管理和治療青光眼的各種診斷設備、手術設備、藥物和治療解決方案。預防視力喪失、顯著改善患者生活品質的需求強調了對先進青光眼治療的需求。應用範圍涵蓋臨床環境、研究機構和醫療機構，利用外科手術的進步、創新的藥物傳遞系統和增強的診斷工具來更好地管理眼內壓和視網膜健康。最終用途範圍廣泛，包括醫院、眼科診所、居家醫療場所以及日益成長的個人化醫療趨勢。市場成長受到手術和診斷設備技術進步、意識提升以及政府支持研究和預防措施的舉措等因素的顯著影響。新的機會在於微創手術技術、基於人工智慧和物聯網的診斷工具以及個人化治療方法的發展。然而，市場成長面臨治療成本高、低收入地區缺乏公平准入以及監管障礙等限制。此外，青光眼複雜的病理生理學及其無症狀性對早期診斷和治療依從性提出了挑戰。基因治療、神經保護、緩釋性藥物傳輸系統和基於遠端醫療的患者管理等領域的創新可以提供競爭優勢。市場的本質是動態的，促進生物技術公司、醫療保健提供者和學術機構之間的合作。鼓勵公司專注於合作研究，投資新的數位健康解決方案，並擴展到開拓的市場，以抓住潛在的成長並改善全球營運。

主要市場統計
基準年[2023] 72.3億美元
預測年份 [2024] 76億美元
預測年份 [2030] 105.6億美元
複合年成長率（%） 5.56%

市場動態：揭示快速發展的青光眼市場的關鍵市場洞察

供需的動態交互作用正在改變青光眼市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 微創手術的採用增加有助於市場擴張（青光眼）
    • 聯合治療在青光眼治療中的廣泛應用推動了市場開拓
    • 由於青光眼管理遠端醫療和遠端監控服務的擴展，市場擴大
    • 透過開發青光眼新型藥物傳輸系統來提高患者的依從性和治療結果
  • 市場限制因素
    • 介紹新的青光眼治療方法 影響監管挑戰和核准過程中的延誤
    • 由於缺乏對青光眼的認知和教育而延誤診斷和治療
  • 市場機會
    • 透過先進的基因療法和個人化醫療方法改變青光眼治療
    • 利用人工智慧和機器學習加強青光眼的早期檢測和管理
    • 開發創新的微創手術技術以改善青光眼患者的預後和康復
  • 市場挑戰
    • 缺乏關於及早發現青光眼症狀的公眾意識和教育
    • 農村和低度開發地區青光眼專業護理的可用性和可近性有限

波特五力：駕馭青光眼市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解青光眼市場的外部影響

外部宏觀環境因素在塑造青光眼市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解青光眼市場的競爭格局

對青光眼市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣青光眼市場供應商的績效評估

FPNV定位矩陣是評估青光眼市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製青光眼市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，青光眼市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 微創手術的增加有助於市場擴張
      • 在治療中增加聯合治療的使用推動了市場的開拓
      • 透過擴大遠端醫療和遠端監控服務來擴大市場範圍
      • 開發新的藥物輸送系統以提高患者的依從性和結果
    • 抑制因素
      • 監管挑戰和緩慢的核准流程影響新青光眼治療方法的推出
      • 缺乏對青光眼的認知和教育導致診斷和治療的延誤
    • 機會
      • 透過先進的基因療法和個人化醫療方法實現青光眼治療的創新
      • 利用人工智慧和機器學習增強青光眼的早期檢測和管理
      • 開發創新的微創手術技術以改善患者的治療效果和康復
    • 任務
      • 大眾缺乏對青光眼症狀早期發現的認知與教育
      • 農村和發展中地區的專科護理較少且難以獲得
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章青光眼市場：依類型

  • 閉角型青光眼
  • 正常眼壓性青光眼
  • 原發性開角型青光眼

第7章 青光眼市場：依診斷方法

  • 房角鏡檢查
  • 眼壓測量
  • 視野測試

第8章青光眼市場：依治療分類

  • 雷射治療
    • 氬氣雷射小梁網整型術
    • 選擇性雷射小梁網整型術
  • 藥物治療
    • α促效劑
    • BETA受體阻斷劑
    • 碳酸酐酶抑制劑
    • 前列腺素琴酒
  • 外科手術
    • 引流植入植入
    • 微創青光眼手術
    • 切除術

第 9 章 青光眼市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 眼科診所
  • 研究所

第10章青光眼市場：依年齡層

  • 成人用
  • 老年病
  • 小兒科

第11章美洲青光眼市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太青光眼市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲青光眼市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • 1. Aerie Pharmaceuticals
  • 2. Alcon
  • 3. Allergan
  • 4. Allergan (acquired by Abbvie)
  • 5. Bausch Health
  • 6. EyeGate Pharmaceuticals
  • 7. Eyenovia
  • 8. Glaukos Corporation
  • 9. Inotek Pharmaceuticals
  • 10. Johnson & Johnson
  • 11. Merck
  • 12. Nicox
  • 13. Novartis
  • 14. Pfizer
  • 15. Regeneron Pharmaceuticals
  • 16. Roche
  • 17. Sanofi
  • 18. Santen Pharmaceutical
  • 19. Teva Pharmaceutical
  • 20. Valeant Pharmaceuticals International
Product Code: MRR-1A1A064C034E

The Glaucoma Market was valued at USD 7.23 billion in 2023, expected to reach USD 7.60 billion in 2024, and is projected to grow at a CAGR of 5.56%, to USD 10.56 billion by 2030.

Glaucoma, a leading cause of irreversible blindness globally, demands extensive market research due to the growing aging population and increasing prevalence of the disease. The scope of this market includes a diverse array of diagnostic equipment, surgical devices, pharmaceuticals, and therapeutic solutions aimed at managing and treating glaucoma. The necessity for advanced glaucoma treatments is underscored by the need to prevent vision loss, thus ensuring a substantial quality of life for patients. Applications span clinical settings, research institutions, and healthcare facilities, utilizing surgical advancements, innovative drug delivery systems, and enhanced diagnostic tools to better manage intraocular pressure and retinal health. The end-use scope is broad, encompassing hospitals, specialized ophthalmology clinics, and home care settings, with an increasing trend toward personalized medicine. Market growth is significantly influenced by factors such as technological advancements in surgical and diagnostic devices, higher awareness among patients due to robust community outreach, and government initiatives to boost research and preventive measures. Emerging opportunities lie in developing minimally invasive surgical techniques, AI and IoT-based diagnostic tools, and personalized therapeutic approaches. However, market growth faces limitations such as high costs of treatment, lack of equitable access in low-income regions, and regulatory hurdles. Moreover, complex pathophysiology of glaucoma and its asymptomatic nature pose challenges in early diagnosis and treatment adherence. Innovating in areas like gene therapy, neuroprotection, sustained-release drug delivery systems, and telemedicine-based patient management could provide a competitive edge. The market's nature is dynamic, fostering collaboration between biotech firms, healthcare providers, and academic institutions. Businesses are recommended to focus on collaborative research, investing in emerging digital health solutions, and expanding into untapped markets to seize latent growth potential and improve glaucoma management on a global scale.

KEY MARKET STATISTICS
Base Year [2023] USD 7.23 billion
Estimated Year [2024] USD 7.60 billion
Forecast Year [2030] USD 10.56 billion
CAGR (%) 5.56%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Glaucoma Market

The Glaucoma Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising adoption of minimally invasive glaucoma surgeries contributing to market expansion
    • Increasing utilization of combination therapies in glaucoma treatment fostering market development
    • Expansion of telemedicine and remote monitoring services for glaucoma management enhancing market reach
    • Development of novel drug delivery systems for glaucoma improving patient compliance and outcomes
  • Market Restraints
    • Regulatory challenges and slow approval process affecting the introduction of new glaucoma therapies
    • Lack of awareness and education about glaucoma leading to delayed diagnosis and treatment
  • Market Opportunities
    • Revolutionizing glaucoma treatment through advanced gene therapy and personalized medicine approaches
    • Leveraging artificial intelligence and machine learning to enhance early glaucoma detection and management
    • Developing innovative and less-invasive surgical techniques for glaucoma patients to improve outcomes and recovery
  • Market Challenges
    • Lack of awareness and education on early detection of glaucoma symptoms among the general population
    • Limited availability and accessibility of specialized glaucoma care in rural and underdeveloped regions

Porter's Five Forces: A Strategic Tool for Navigating the Glaucoma Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Glaucoma Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Glaucoma Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Glaucoma Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Glaucoma Market

A detailed market share analysis in the Glaucoma Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Glaucoma Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Glaucoma Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Glaucoma Market

A strategic analysis of the Glaucoma Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Glaucoma Market, highlighting leading vendors and their innovative profiles. These include Aerie Pharmaceuticals, Alcon, Allergan, Allergan (acquired by Abbvie), Bausch Health, EyeGate Pharmaceuticals, Eyenovia, Glaukos Corporation, Inotek Pharmaceuticals, Johnson & Johnson, Merck, Nicox, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, Santen Pharmaceutical, Teva Pharmaceutical, and Valeant Pharmaceuticals International.

Market Segmentation & Coverage

This research report categorizes the Glaucoma Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Angle-Closure Glaucoma, Normal-Tension Glaucoma, and Primary Open-Angle Glaucoma.
  • Based on Diagnosis Method, market is studied across Gonioscopy, Tonometry, and Visual Field Test.
  • Based on Treatment, market is studied across Laser Treatment, Medication, and Surgery. The Laser Treatment is further studied across Argon Laser Trabeculoplasty and Selective Laser Trabeculoplasty. The Medication is further studied across Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors, and Prostaglandin Analogs. The Surgery is further studied across Drainage Implants, Minimally Invasive Glaucoma Surgery, and Trabeculectomy.
  • Based on End-User, market is studied across Ambulatory Surgery Centers, Hospitals, Ophthalmic Clinics, and Research Institutes.
  • Based on Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising adoption of minimally invasive glaucoma surgeries contributing to market expansion
      • 5.1.1.2. Increasing utilization of combination therapies in glaucoma treatment fostering market development
      • 5.1.1.3. Expansion of telemedicine and remote monitoring services for glaucoma management enhancing market reach
      • 5.1.1.4. Development of novel drug delivery systems for glaucoma improving patient compliance and outcomes
    • 5.1.2. Restraints
      • 5.1.2.1. Regulatory challenges and slow approval process affecting the introduction of new glaucoma therapies
      • 5.1.2.2. Lack of awareness and education about glaucoma leading to delayed diagnosis and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Revolutionizing glaucoma treatment through advanced gene therapy and personalized medicine approaches
      • 5.1.3.2. Leveraging artificial intelligence and machine learning to enhance early glaucoma detection and management
      • 5.1.3.3. Developing innovative and less-invasive surgical techniques for glaucoma patients to improve outcomes and recovery
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness and education on early detection of glaucoma symptoms among the general population
      • 5.1.4.2. Limited availability and accessibility of specialized glaucoma care in rural and underdeveloped regions
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Glaucoma Market, by Type

  • 6.1. Introduction
  • 6.2. Angle-Closure Glaucoma
  • 6.3. Normal-Tension Glaucoma
  • 6.4. Primary Open-Angle Glaucoma

7. Glaucoma Market, by Diagnosis Method

  • 7.1. Introduction
  • 7.2. Gonioscopy
  • 7.3. Tonometry
  • 7.4. Visual Field Test

8. Glaucoma Market, by Treatment

  • 8.1. Introduction
  • 8.2. Laser Treatment
    • 8.2.1. Argon Laser Trabeculoplasty
    • 8.2.2. Selective Laser Trabeculoplasty
  • 8.3. Medication
    • 8.3.1. Alpha Agonists
    • 8.3.2. Beta Blockers
    • 8.3.3. Carbonic Anhydrase Inhibitors
    • 8.3.4. Prostaglandin Analogs
  • 8.4. Surgery
    • 8.4.1. Drainage Implants
    • 8.4.2. Minimally Invasive Glaucoma Surgery
    • 8.4.3. Trabeculectomy

9. Glaucoma Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgery Centers
  • 9.3. Hospitals
  • 9.4. Ophthalmic Clinics
  • 9.5. Research Institutes

10. Glaucoma Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Pediatric

11. Americas Glaucoma Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Glaucoma Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Glaucoma Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aerie Pharmaceuticals
  • 2. Alcon
  • 3. Allergan
  • 4. Allergan (acquired by Abbvie)
  • 5. Bausch Health
  • 6. EyeGate Pharmaceuticals
  • 7. Eyenovia
  • 8. Glaukos Corporation
  • 9. Inotek Pharmaceuticals
  • 10. Johnson & Johnson
  • 11. Merck
  • 12. Nicox
  • 13. Novartis
  • 14. Pfizer
  • 15. Regeneron Pharmaceuticals
  • 16. Roche
  • 17. Sanofi
  • 18. Santen Pharmaceutical
  • 19. Teva Pharmaceutical
  • 20. Valeant Pharmaceuticals International

LIST OF FIGURES

  • FIGURE 1. GLAUCOMA MARKET RESEARCH PROCESS
  • FIGURE 2. GLAUCOMA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GLAUCOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GLAUCOMA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GLAUCOMA MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GLAUCOMA MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GLAUCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GLAUCOMA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GLAUCOMA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GLAUCOMA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES GLAUCOMA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES GLAUCOMA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. GLAUCOMA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. GLAUCOMA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GLAUCOMA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GLAUCOMA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GLAUCOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GLAUCOMA MARKET DYNAMICS
  • TABLE 7. GLOBAL GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GLAUCOMA MARKET SIZE, BY ANGLE-CLOSURE GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GLAUCOMA MARKET SIZE, BY NORMAL-TENSION GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GLAUCOMA MARKET SIZE, BY PRIMARY OPEN-ANGLE GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GLAUCOMA MARKET SIZE, BY GONIOSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GLAUCOMA MARKET SIZE, BY TONOMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GLAUCOMA MARKET SIZE, BY VISUAL FIELD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GLAUCOMA MARKET SIZE, BY LASER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GLAUCOMA MARKET SIZE, BY ARGON LASER TRABECULOPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GLAUCOMA MARKET SIZE, BY SELECTIVE LASER TRABECULOPLASTY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GLAUCOMA MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GLAUCOMA MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GLAUCOMA MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GLAUCOMA MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GLAUCOMA MARKET SIZE, BY PROSTAGLANDIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GLAUCOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GLAUCOMA MARKET SIZE, BY DRAINAGE IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GLAUCOMA MARKET SIZE, BY MINIMALLY INVASIVE GLAUCOMA SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GLAUCOMA MARKET SIZE, BY TRABECULECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GLAUCOMA MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GLAUCOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GLAUCOMA MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GLAUCOMA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GLAUCOMA MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GLAUCOMA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL GLAUCOMA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES GLAUCOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. CHINA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. INDIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. INDIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. INDONESIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. INDONESIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. INDONESIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 133. JAPAN GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. JAPAN GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. JAPAN GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. JAPAN GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. MALAYSIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 141. MALAYSIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. MALAYSIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. MALAYSIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. MALAYSIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. PHILIPPINES GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. PHILIPPINES GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. PHILIPPINES GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. SINGAPORE GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 157. SINGAPORE GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. SINGAPORE GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. SINGAPORE GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SINGAPORE GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH KOREA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH KOREA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH KOREA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. TAIWAN GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 173. TAIWAN GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. TAIWAN GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. TAIWAN GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. TAIWAN GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. THAILAND GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 181. THAILAND GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. THAILAND GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. THAILAND GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. THAILAND GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. VIETNAM GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 189. VIETNAM GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. VIETNAM GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. VIETNAM GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. VIETNAM GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA GLAUCOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. DENMARK GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 206. DENMARK GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. DENMARK GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 208. DENMARK GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. DENMARK GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. EGYPT GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 214. EGYPT GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 215. EGYPT GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 216. EGYPT GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 217. EGYPT GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. FINLAND GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 222. FINLAND GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 223. FINLAND GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. FINLAND GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. FINLAND GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. FRANCE GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 230. FRANCE GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. FRANCE GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 232. FRANCE GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. FRANCE GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. GERMANY GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 238. GERMANY GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 239. GERMANY GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 240. GERMANY GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 241. GERMANY GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. ISRAEL GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 246. ISRAEL GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 247. ISRAEL GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 248. ISRAEL GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. ISRAEL GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. ITALY GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 254. ITALY GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 255. ITALY GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 256. ITALY GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 257. ITALY GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 262. NETHERLANDS GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 264. NETHERLANDS GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. NIGERIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 270. NIGERIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 271. NIGERIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 272. NIGERIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. NIGERIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. NORWAY GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 278. NORWAY GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 279. NORWAY GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 280. NORWAY GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 281. NORWAY GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. POLAND GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 286. POLAND GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 287. POLAND GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 288. POLAND GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 289. POLAND GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. QATAR GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 294. QATAR GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 295. QATAR GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 296. QATAR GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 297. QATAR GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. RUSSIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 302. RUSSIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 303. RUSSIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 304. RUSSIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 305. RUSSIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 306. RUSSIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. RUSSIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 310. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 312. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 314. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 316. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 318. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 320. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 322. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 324. SPAIN GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. SPAIN GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 326. SPAIN GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 327. SPAIN GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 328. SPAIN GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 329. SPAIN GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 330. SPAIN GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 331. SPAIN GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 332. SWEDEN GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. SWEDEN GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 334. SWEDEN GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 335. SWEDEN GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 336. SWEDEN GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 337. SWEDEN GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 338. SWEDEN GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 339. SWEDEN GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 340. SWITZERLAND GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 342. SWITZERLAND GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 344. SWITZERLAND GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 346. SWITZERLAND GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 348. TURKEY GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 349. TURKEY GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 350. TURKEY GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 351. TURKEY GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 352. TURKEY GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 353. TURKEY GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 354. TURKEY GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 355. TURKEY GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 356. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 358. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 359. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 360. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 361. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 362. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 363. UNITED ARAB EMIRATES GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 364. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 365. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
  • TABLE 366. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 367. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY LASER TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 368. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 369. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 370. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 371. UNITED KINGDOM GLAUCOMA MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 372. GLAUCOMA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 373. GLAUCOMA MARKET, FPNV POSITIONING MATRIX, 2023